HOXB9 and neoplasm: In contrast to the SKOV3ip1-EV tumours where miR-192 treatment resulted in a 90% reduction in tumour burden, only 65 and 30% reduction in tumour burden was observed for tumours expressing EGR1 and HOXB9, respectively (Fig. 4g).